The Organic Chemistry of Drug Synthesis, Volume 7 - Lednicer, Daniel
206,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
103 °P sammeln
  • Gebundenes Buch

THE CLASSIC REFERENCE ON THE SYNTHESIS OF MEDICINAL AGENTS --NOW COMPLETELY UPDATED The seventh volume in the definitive series that provides a quick yet thorough overview of the synthetic routes used to access specific classes of therapeutic agents, this volume covers approximately 220 new non-proprietary drug entities introduced since the publication of Volume 6. Many of these compounds represent novel structural types first identified by sophisticated new cell-based assays. Specifically, a significant number of new antineoplastic and antiviral agents are covered. As in the previous volumes,…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
THE CLASSIC REFERENCE ON THE SYNTHESIS OF MEDICINAL AGENTS --NOW COMPLETELY UPDATED The seventh volume in the definitive series that provides a quick yet thorough overview of the synthetic routes used to access specific classes of therapeutic agents, this volume covers approximately 220 new non-proprietary drug entities introduced since the publication of Volume 6. Many of these compounds represent novel structural types first identified by sophisticated new cell-based assays. Specifically, a significant number of new antineoplastic and antiviral agents are covered. As in the previous volumes, materials are organized by chemical class and syntheses originate with available starting materials. Organized to make the information accessible, this resource covers disease state, rationale for method of drug therapy, and the biological activities of each compound and preparation. The Organic Chemistry of Drug Synthesis, Volume 7 is a hands-on reference for medicinal and organic chemists, and a great resource for graduate and advanced undergraduate students in organic and medicinal chemistry.
Autorenporträt
DANIEL LEDNICER, PHD, is the author of several books on drug synthesis and discovery. His career in both the private and public sectors has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. Following that, he served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute.